… therapy had response rate of 18.56%. However, this study showed no OS advantage of any
one regimen. … -2 produced durable objective responses in patients with metastatic melanoma …

… Because NT is becoming the standard of care for patients with BRPC … composition and
clinical response. In this context, it may be proposed that screening changes in body composition …

… Herein, we have assessed a large cohort of patients treated with anti–PD-1/PD-L1 to identify
the long-term immune toxicities, health outcomes, body composition metrics and health-…

… (➅) Resistance models incorporate mechanisms related to the emergence of resistance to
therapy over time. (➆) Biomarkers of disease progression and treatment response in different …

… all patients benefit from standard treatment regimens (1,2), resulting in undertreatment or
overtreatment in many women. Predicting treatment response is … For the treatment regimen, we …

… Before a new RR/MDR treatment regimen composed of bedaquiline and linezolid can be …
drug in the treatment regimen of RR/MDR-TB given that such a regimen is widely accessible …

… cannot be fully discarded, it must be stressed that the use of these regimens was extremely
limited in our cohort, and thus their contribution in the changes in the waiting list or post-LT …

… toxicity to ipilimumab in patients with metastatic melanoma. A … in body composition that occur
during treatment and to assess … -treatment CT images taken as part of routine patient care …

… a de novo lack of treatment response, whereas acquired … mutated NSCLC patients who
achieve an effective response or … while they are still on the targeted therapy (Jackman et al., 2010)…

… treatment regimens … composition of treatment regimens for MDR-TB. We propose to reserve
the term ‘core drug’ for the one drug in a regimen that contributes most to relapse-free cure. …